Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Shigellosis: early-phase trial registry
1 of 4 indexed Shigellosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Shigellosis: 4 US clinical trials tracked, 1 recruiting.
Shigellosis is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is LimmaTech Biologics, running 3 of these trials.
Enrollment posture brief
Registry condition shigellosis
OPEN 1 | RECR 25% | LATE 0 | EARLY 4 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Shigellosis lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Shigellosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Shigellosis is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
LimmaTech Biologics
NCT06615375
Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis
Intralytix
NCT05182749
Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a
LimmaTech Biologics
NCT02646371
Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a
LimmaTech Biologics
NCT02388009
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Shigellosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Shigellosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Shigellosis page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Shigellosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- LimmaTech Biologics sponsors the most Shigellosis trials on record, review their full trial history before evaluating a specific study. See LimmaTech Biologics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Shigellosis condition card totals 4 registered trials; most-linked intervention Placebo; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.